Non-Amphetamine Treatment Options for ADHD

Methylphenidate (Non-Amphetamine Stimulant)

The American Academy of Pediatrics recommends methylphenidate as the preferred non-amphetamine option for ADHD treatment, with large effect sizes for core symptoms and 70-80% response rates 1, 3
Long-acting formulations of methylphenidate are strongly preferred over immediate-release due to better adherence, lower rebound risk, and 8-12 hours of symptom control 3, 4
The American Academy of Child and Adolescent Psychiatry suggests starting with 5-10 mg of methylphenidate in the morning after breakfast for adults, titrating by 5-10 mg increments weekly based on response and tolerability 4

The American Academy of Pediatrics recommends considering non-stimulants when methylphenidate is ineffective, not tolerated, or contraindicated, particularly in patients with comorbid substance use disorders, severe anxiety, tics/Tourette's, or sleep disturbances 2, 6
Atomoxetine is the primary non-stimulant alternative, offering "around-the-clock" effects without controlled substance status, with a medium effect size compared to stimulants but superior to placebo 2, 6
The National Institute of Mental Health suggests that guanfacine (extended-release) and clonidine (extended-release) provide alternative non-stimulant options with effect sizes around 0.7, particularly useful as adjunctive therapy or when sedation is beneficial 2, 3

The American Psychiatric Association recommends bupropion XL as a second-line non-stimulant alternative when other options are contraindicated or ineffective, with a start dose of 150 mg once daily in the morning and a maximum dose of 450 mg per day 3, 4
Viloxazine is an additional non-stimulant option for adult ADHD treatment, although limited evidence is provided in current guidelines 3, 5

The American Academy of Pediatrics suggests a treatment algorithm starting with initial assessment, including screening for cardiovascular disease and active substance use disorder, followed by first-line treatment selection, and augmentation strategy if necessary 1, 4, 6
The algorithm recommends initiating long-acting methylphenidate if no contraindications to stimulants, or atomoxetine if stimulants are contraindicated or the patient refuses controlled substances 1, 2, 6

The National Institute of Mental Health warns against expecting rapid onset with non-stimulants, as atomoxetine requires 6-12 weeks and alpha-2 agonists require 2-4 weeks for full effect 2, 6
The American Academy of Child and Adolescent Psychiatry advises against starting atomoxetine at excessively high doses, beginning conservatively and titrating slowly, and against discontinuing stimulants abruptly for "drug holidays" during important events 4